Invex Therapeutics Ltd Price Chart
Invex Therapeutics Ltd IXC.XA Financial and Trading Overview
| Invex Therapeutics Ltd stock price | 0.08 AUD |
| Previous Close | 0.45 AUD |
| Open | 0.45 AUD |
| Bid | 0.38 AUD x N/A |
| Ask | 0.46 AUD x N/A |
| Day's Range | 0.45 - 0.45 AUD |
| 52 Week Range | 0.35 - 0.66 AUD |
| Volume | 2.34K AUD |
| Avg. Volume | 7.65K AUD |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.759411 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.04 AUD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
IXC.XA Valuation Measures
| Enterprise Value | 8.4M AUD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.3677812 |
| Enterprise Value/Revenue | 46.064 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Invex Therapeutics Ltd Stock Price History
| Beta (5Y Monthly) | 0.759411 |
| 52-Week Change | 0% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.66 AUD |
| 52 Week Low | 0.35 AUD |
| 50-Day Moving Average | 0.43 AUD |
| 200-Day Moving Average | 0.5 AUD |
IXC.XA Share Statistics
| Avg. Volume (3 month) | 7.65K AUD |
| Avg. Daily Volume (10-Days) | 8.82K AUD |
| Shares Outstanding | N/A |
| Float | 55.61M |
| Short Ratio | N/A |
| % Held by Insiders | 52.68% |
| % Held by Institutions | 2.31% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -3652.94% |
| Gross Margin | 12.43% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -14.49% |
| Return on Equity (ttm) | -21.72% |
Income Statement
| Revenue (ttm) | 182.25K AUD |
| Revenue Per Share (ttm) | 0.002 AUD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 182.25K AUD |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -6005352 AUD |
| Diluted EPS (ttm) | -0.04 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 25.42M AUD |
| Total Cash Per Share (mrq) | 0.34 AUD |
| Total Debt (mrq) | 0 AUD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 22.293 |
| Book Value Per Share (mrq) | 0.329 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -5942096 AUD |
| Levered Free Cash Flow (ttm) | -4099482 AUD |
Profile of Invex Therapeutics Ltd
| Country | Australia |
| State | WA |
| City | Perth |
| Address | 38 Rowland Street |
| ZIP | 6008 |
| Phone | 61 8 6382 0137 |
| Website | https://www.invextherapeutics.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | N/A |
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.
Q&A For Invex Therapeutics Ltd Stock
What is a current IXC.XA stock price?
Invex Therapeutics Ltd IXC.XA stock price today per share is 0.08 AUD.
How to purchase Invex Therapeutics Ltd stock?
You can buy IXC.XA shares on the Cboe AU exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Invex Therapeutics Ltd?
The stock symbol or ticker of Invex Therapeutics Ltd is IXC.XA.
How many shares does Invex Therapeutics Ltd have in circulation?
The max supply of Invex Therapeutics Ltd shares is 0.
What is Invex Therapeutics Ltd Price to Earnings Ratio (PE Ratio)?
Invex Therapeutics Ltd PE Ratio is now.
What was Invex Therapeutics Ltd earnings per share over the trailing 12 months (TTM)?
Invex Therapeutics Ltd EPS is -0.04 AUD over the trailing 12 months.